Hangwen Li

机构：University of Science and Technology of China, Mirna Therapeutics (United States), Shanghai East Hospital, National Institute for Viral Disease Control and Prevention · ORCID：0009-0007-8852-4501

发表论文 53 篇 · 总被引 3651 次 · h-index 19

代表论文

• Algorithm for optimized mRNA design improves stability and immunogenicity (2023 · Nature · 被引 468)
• Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients (2021 · Signal Transduction and Targeted Therapy · 被引 125)
• Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity (2024 · Science Advances · 被引 56)
• An mRNA vaccine elicits STING-dependent antitumor immune responses (2022 · Acta Pharmaceutica Sinica B · 被引 37)
• A single immunization with core–shell structured lipopolyplex mRNA vaccine against rabies induces potent humoral immunity in mice and dogs (2023 · Emerging Microbes & Infections · 被引 29)
• An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants (2024 · Journal of Controlled Release · 被引 20)